A multicenter, open-label study investigating efficacy and safety of GB-0998 for antibody-mediated rejection after renal transplant

akagawa Ken0 个研究点目标入组 20 人开始时间: 2020年10月28日最近更新: 2023年10月17日

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 20

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 16age old 至 ot applicable（—）
性别: All

入选标准

•1.Male and female patients aged 16 years or older at the time of providing informed consent
•2.Patients who receive explanation using the informed consent form and patient information sheet approved by an institutional review board and provide the signed informed consent form before conducting procedures specified in the study (If the patient is a minor, both patient himself/herself and legally acceptable representative* must sign the informed consent form.)
•3.Patients who meet the following criteria and are judged by the investigator or subinvestigator to develop AMR after renal transplant:
•1)AMR due to anti-HLA antibody, anti-non-HLA antibody, anti-A antibody, and/or anti-B antibody judged by the investigator or subinvestigator based on the antibody test results in the screening period
•2)Active/chronic active AMR of the Banff classification (2017); note that electron microscopy and genetic marker testing specified in the Banff classification are not essential
•3)For chronic active AMR, the serum creatinine level determined by the pre-enrollment laboratory test does not exceed 2.5 mg/d

排除标准

•Patients who fall under any of the following items are excluded from the study
•1.Patients who received prohibited concomitant medications, which are specified separately, in the period between providing informed consent and initiation of study treatment
•2.Patients who are receiving a dialysis treatment or who are judged by the investigator or subinvestigator to require that
•3.Patients with T cell-mediated rejection (TCMR) however,patients with a diagnosis of mixed rejection of AMR and TCMR are to be included in the study
•4.Patients who have a concurrent severe hepatic/cardiovascular disease that requires hospitalization and are judged by the investigator or subinvestigator to be inappropriate as subjects of the study.
•5.Patients receiving treatment for malignant tumor
•6.Patients who concurrently have thromboembolism or who are judged by the investigator or subinvestigator to be at high risk for the onset of that, for example, patients with a history of thromboembolism
•7.Patients with a serum IgA level of <5 mg/dL, as a result of the laboratory test in the screening period.If a serum IgA level has been confirmed by the previous laboratory test, this measurement is unnecessary.
•8.Patients who need a constant treatment with IVIG at the time of providing informed consent (e.g., chronic inflammatory demyelinating polyradiculoneuropathy)
•9.Pregnant, pregnancy test-positive, parturient, or lactating women or patients with pregnancy intentions during the study period. A pregnancy test is conducted by measurement of serum chorionic gonadotropin. However, women who meet the following conditions can skip the pregnancy test by recording which condition is met.
•History of bilateral salpingo-oophorectomy or hysterectomy
•Premature ovarian failure confirmed by a specialist physician
•Postmenopause (amenorrhea for continuous 12 months without other medical causes)
•10.Patients who received other study drugs within 90 days before providing informed consent or who are participating in other clinical studies at the time of providing informed consent
•11.Patients with a history of hypersensitivity against the ingredient of the study drug
•12.Patients who are judged by the investigator or subinvestigator to be inappropriate as subjects of the study

研究者

发起方

akagawa Ken

相似试验

进行中（未招募）

1 期

A study to assess the efficacy and safety of potassium clavulanate/amoxicillin in the treatment of children with acute bacterial sinusitisAcute Bacterial Rhinosinusitis

EUCTR2015-004907-22-Outside-EU/EEAMedicines Development (Infectious Diseases)27

进行中（未招募）

不适用

A multicenter, open label study to assess the effect of trastuzumab + Whole Brain Radiotherapy (WBRT) on brain metastases from HER-2 positive breast cancer. - bHERt2Stage IV, HER-2 positive breast cancer patients with brain metastasis and who are eligible for WBRT.MedDRA version: 13.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2010-021191-29-ITROCHE

进行中（未招募）

不适用

A multicenter open label study to explore the efficacy and tolerability of Tenofovir DF (TDF) (300 mg) in chronic hepatitis B, HBeAg positive or negative, patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment, defined as HBV-DNA levels > 10.000 copies/ml after an ADV or ADV+LAM treatment of > 48 weeks - OptiB: Optimizing treatment for Chronic Hepatitis B patientsChronic Hepatitis B HBVMedDRA version: 14.1Level: PTClassification code 10019731Term: Hepatitis BSystem Organ Class: 10021881 - Infections and infestations

EUCTR2007-001789-34-ITAZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA

进行中（未招募）

不适用

A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: Contraception

EUCTR2005-004978-25-HUInternational Committee for Contraception Research of the Population Council2,200

进行中（未招募）

不适用

EUCTR2005-004978-25-SEInternational Committee for Contraception Research of the Population Council2,200